People don't buy consumer wearables just to count steps anymore. They want early warnings, useful health signals, and features they can trust.

The Touchstone Sands Capital Select Growth Fund (Class A Shares, Load Waived) underperformed its benchmark, the Russell 1000® ...

Tandem Diabetes Care (NasdaqGM:TNDM) has enabled compatibility of its Tandem Mobi automated insulin delivery system with select Android smartphones in the U.S. This Android rollout expands access to ...

Dexcom will present the full data from several studies at the Advanced Technologies and Treatments for Diabetes conference, ...

(NASDAQ:DXCM), the global leader in glucose biosensing, will present new findings that showcase the benefits of its glucose biosensing technology for people with all types of diabetes and share more ...

Shares of DexCom Inc. DXCM shed 1.38% to $67.79 Tuesday, on what proved to be an all-around poor trading session for the stock market, with the S&P 500 Index SPX falling 0.21% to 6,781.48 and Dow ...

In the preceding three months, 12 analysts have released ratings for DexCom (NASDAQ:DXCM), presenting a wide array of ...

Dexcom will stop producing G6 CGM sensors July 1, 2026, urging patients to switch to the smaller, more accurate G7 model.

The Stelo is available to anyone who wants to monitor their blood glucose, no prescription needed. But as an active adult without diabetes, are these extra data points worth $99 per month?

This medical technology firm delivers advanced noninvasive monitoring and automation solutions to healthcare providers worldwide.

Dexcom ( (DXCM)) just unveiled an update. On February 26, 2026, Dexcom’s board expanded to twelve members and appointed Rick Osterloh, Google’s Senior Vice President for Platforms & Devices, as an ...

Two major upgrades to Fitbit’s AI Coach aim to improve sleep insights and to use your medical records to inform its advice.